ProShares Ultra Health Care ETF

Eli Lilly to Participate in the BIO International Convention 2026

TIGER GLOBAL Cuts Stake in UnitedHealth Group by 16.6%

Morgan Stanley reiterates 'Overweight' rating on Eli Lilly, citing strong international growth prospects

UnitedHealth Doubles Down on AI and Tracks Employee Usage to Boost Efficiency

Eli Lilly launches Alzheimer's drug Donanemab in India

Mubadala Increases Stakes in AbbVie and Match Group, Reduces CVS and Gilead Holdings in Q1

Bernstein reiterates 'Outperform' rating on UnitedHealth with a $444 price target

Eli Lilly announces an additional $4.5 billion investment in its Lebanon, Indiana manufacturing site

Competitor Novo Nordisk partners with OpenAI to accelerate drug development

Bank of America raises UnitedHealth's price target after positive remarks from CFO at conference

Phoenix Financial Increases Stake in UnitedHealth (UNH) by 11.8%, Worth $15.3 Million

Barclays Maintains 'Buy' Rating on Eli Lilly with a $1400 Price Target

AbbVie's Ekali approved by NMPA for combination therapy in R/R follicular lymphoma

Eli Lilly executive points out at DIA conference that pharmaceutical innovation needs to focus on quality over quantity, warning against homogenized competition.

Lilly China Executive Emphasizes Patient-Centric Drug Innovation at DIA Conference

Allworth Financial LP Increases Merck Holdings by 71.4%

UnitedHealth's Optum to Participate in AAPA National Conference

Guggenheim Analyst Raises Eli Lilly's Price Target to $1,235

China Tightens Sales Regulations on GLP-1 Drugs Like Eli Lilly's Tirzepatide

Study Suggests Patients Maintain Weight Loss After Switching to Lilly's Oral Obesity Pill

HCW Biologics

P3 Health Partners

Murano Global BV

Auddia

Super League Enterprise

Trio-Tech Int

Ernexa Therapeutics

Robostrategy

Jiade

IBBQ

SBIO

Tigerlily Foundation has partnered with Bristol Myers Squibb to enhance access to clinical trials for young women, particularly women of color. This collaboration aims to reduce barriers to participation and increase awareness through the ONE in a MILLION campaign, which seeks to educate one million women about clinical trials. The initiative emphasizes the importance of diversity in research to improve health equity and treatment effectiveness.

prnewswire

Bristol Myers Squibb

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Direxion Pharma & Medical Bull 3X

iShares US Pharma

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

VG Health

VanEck Biotech ETF

ALPS Medical Breakthrough

Bristol-Myers Squibb Company

09:24 ETTigerlily Foundation Collaborates with Bristol Myers Squibb to Advance Clinical Trial Access and Equity

MADE

W.W. Grainger VP Laurie Thomson sold 313 shares at $1,231.69 each, totaling $385,518.97, reducing her stake by 43.96%. Post-sale, she holds 399 shares valued at $491,444.31. The transaction was filed with the SEC. The stock recently traded at $1,281.74, with a market cap of $60.51 billion and a P/E ratio of 34.51. Grainger reported $11.65 EPS for the last quarter, exceeding estimates, and announced a dividend increase to $2.49 per share, payable June 1. Institutional investors own 80.70% of the stock.

Market Beat

WW Grainger

Spdr Select Indu

VG Industr

iShares U.S. Manufacturing ETF

Genuine Parts

Fastenal

T. Rowe Price

Barclays

Oppenheimer

W.W. Grainger (NYSE:GWW) VP Laurie Thomson Sells 313 Shares

CURE

Molina Healthcare Inc. (MOH) shares rose 3.45% to $191.58 on Tuesday, ending a three-day losing streak, despite underperforming compared to competitors like Humana Inc. and Centene Corp., which saw gains of 7.69% and 5.23%, respectively. The stock remains 41.53% below its 52-week high of $327.68 reached on May 20. Trading volume was 954,383, significantly below the 50-day average of 1.6 million shares.

MarketWatch Automated

Molina Healthcare

iShares US Healthcare Providers

Direxion Healthcare Bull 3X

SPDR S&P Health

Dow Jones Industrial Average

S&P 500

Humana

Centene

Factset Research

Molina Healthcare Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains

600276

Bristol Myers Squibb (BMS) and Hengrui Pharma have formed a global strategic collaboration and licensing agreement covering 13 early-stage programs in oncology, hematology, and immunology. Announced on May 12, 2026, the deal includes a $950 million payment structure, with BMS paying $600 million upfront. The collaboration aims to leverage BMS's global capabilities and Hengrui's discovery platforms to accelerate the development of new therapies. BMS will hold exclusive rights to Hengrui-originated assets outside certain territories, while Hengrui will manage proof-of-concept activities and may co-develop selected assets.

Pharmexec

Hengrui Pharma

HENGRUI PHARMA

<![CDATA[Bristol Myers Squibb, Hengrui Pharma Form $15.2 Billion Strategic Drug Development Collaboration]]>

01276

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Pharmaceutical Technology

E Fund CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Direxion S&P Biotech Bear 3X

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI 300 Health Care ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Yinhua CSI Innovative Drugs Industry ETF

Tianhong CNI BIOMEDICINE ETF

Guotai CSI Bio-medicine ETF

Penghua SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

BMS and Hengrui forge $15.2bn alliance for early-stage drugs

Forus has raised over $160M to enhance the delivery of modern medicine. The company, formerly known as Tandem, aims to connect doctors, pharmacies, payers, and biopharma through an AI-powered network, streamlining the process of getting new therapies to patients. Backed by prominent investors like Thrive Capital and General Catalyst, Forus addresses the inefficiencies in the current healthcare system, which often delays or prevents patients from receiving necessary treatments. The platform is already in use across all 50 states, supporting millions of patients and expanding rapidly in various medical specialties.

MorningStar

iShares US Medical Devices

ChinaAMC CSI All Share Health Care Devices ETF

SPDR S&P Health Equip

Proshares UltraShort Nasdaq Biotech

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

General Catalyst Global Resilience Merger - Unit

Accel ENT

Bain Capital Specialty Finance

Forus Raises $160M to Build the Foundation for Modern Medicine

Bristol-Myers Squibb (BMY) shares have declined for seven consecutive sessions, dropping 0.9% to $55.64 on Monday. The stock has fallen 3.5% in the previous six sessions and is down 5% over the past month, although it has increased 4% year-to-date. The company recently reported better-than-expected Q1 results.

Bristol-Myers Squibb shares fell for seventh consecutive session

RSPH

Molina Healthcare shareholders approved governance and bylaw changes at the May 6, 2026 annual meeting. Key amendments allow stockholders with at least 20% voting power to call special meetings. The board adopted new bylaws detailing procedural safeguards. Shareholders elected ten directors, ratified Ernst & Young as auditor, and increased shares under the 2025 Equity Incentive Plan. The latest analyst rating for MOH stock is a Buy with a $250 price target, though concerns about recent fundamentals and valuation persist. Molina Healthcare focuses on providing health insurance to low-income populations.

Tip Ranks

Invesco S&P 500 Equal Weight Health Care ETF

Molina Healthcare Shareholders Approve Governance and Bylaw Changes

Centric Wealth Management has reduced its stake in Molina Healthcare, Inc (NYSE:MOH) by 74.3%, now holding 3,100 shares valued at $562,000. Other institutional investors have also adjusted their positions in the company. Molina Healthcare's stock opened at $186.07, with a market cap of $9.69 billion and a PE ratio of 55.05. Analysts have mixed ratings on the stock, with a consensus rating of "Hold" and an average price target of $169.60. The company specializes in government-sponsored health insurance programs.

Rakuten Group, Inc.

Mizuho Financial Group, Inc.

Mizuho Financial

Deutsche Bank AG

Goldman Sachs

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

GS Hldg R

Centric Wealth Management Cuts Stock Position in Molina Healthcare, Inc $MOH

Bristol Myers Squibb (NYSE:BMY) highlighted its growth portfolio and pipeline development during its 2026 annual meeting, where shareholders approved all management proposals. CEO Christopher Boerner reported a total revenue of $48.2 billion for 2025, with over half from its growth portfolio, which includes seven products exceeding $1 billion in sales. The company aims to deliver over 10 new medicines by 2030 and has received 18 approvals in 2025. Shareholders rejected a proposal for an independent board chair, supporting the current leadership structure.

BioNTech SE

Bristol Myers Squibb Touts Pipeline Gains as Shareholders Back Board at Annual Meeting

ProShares Ultra Health Care ETF(RXL.US)